Quick Answer
Insight Molecular Diagnostics Inc. reported Gross Profit of $2.30 million for fiscal year 2025.
Insight Molecular Diagnostics Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $2.30M | +210.5% |
| 2024 | $740.0K | +79.2% |
| 2023 | $413.0K | +2394.4% |
| 2022 | -$18.0K | -101.3% |
| 2021 | $1.42M | +322.2% |
| 2020 | -$639.0K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $139.0K | +178.0% | -60.3% |
| June 30, 2025 | $350.0K | +600.0% | -73.6% |
| March 31, 2025 | $1.32M | +2844.4% | +2550.0% |
| September 30, 2024 | $50.0K | -79.8% | +0.0% |
| June 30, 2024 | $50.0K | -81.6% | +11.1% |
| March 31, 2024 | $45.0K | +350.0% | -81.9% |
| September 30, 2023 | $248.0K | +192.2% | -8.8% |
| June 30, 2023 | $272.0K | +777.4% | +2620.0% |
- Insight Molecular Diagnostics Inc. showed an increase of +210.5% in Gross Profit compared to the prior fiscal year.
- Over the 2020–2025 period, Insight Molecular Diagnostics Inc.’s gross profit has grown by 459.6% (from -$639.0 thousand to $2.30 million).
- The most recent figure is from Insight Molecular Diagnostics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: